Meetings - The ASCO Post

/ Treatment Approaches to Relapsed Refractory CLL What Comes Next

Case 3: Third-Line Treatment of CLL With Deletion 13q, Trisomy 12, and Unmutated IGHV

This is Part 3 of Treatment Approaches to Relapsed/Refractory CLL: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, ...

/ Treatment Approaches to Relapsed Refractory CLL What Comes Next

Case 2: Second-Line Treatment of CLL With Deletion 11q and Unmutated IGHV

This is Part 2 of Treatment Approaches to Relapsed/Refractory CLL: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, ...

/ Treatment Approaches to Relapsed Refractory CLL What Comes Next

Case 1: Front-Line Treatment of CLL With Deletion 13q, Trisomy 12, and Unmutated IGHV

This is Part 1 of Treatment Approaches to Relapsed/Refractory CLL: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. To set the stag...

Treatment Approaches to Relapsed Refractory CLL What Comes Next

Case 3: Third-Line Treatment of CLL With Deletion 13q, Trisomy 12, and Unmutated IGHV

Case 2: Second-Line Treatment of CLL With Deletion 11q and Unmutated IGHV

Case 1: Front-Line Treatment of CLL With Deletion 13q, Trisomy 12, and Unmutated IGHV

Statin Use May Improve Survival With Targeted Therapy for CLL SLL

FDA Approves Anti–PD-1 Antibody for Nasopharyngeal Cancer

W Kimryn Rathmell Named CEO of The Ohio State James Cancer Hospital and Solove Research Institute

Polygenic Risk Score for Prostate Cancer Screening

Is This the End of Cancer Research as We Know It?